What obsessive-compulsive disorder is
Obsessive-compulsive disorder (OCD) is a mental health condition characterised by persistent, intrusive, and unwanted thoughts, images, or urges (obsessions) that generate anxiety or distress, and by repetitive behaviours or mental acts (compulsions) that the person feels driven to perform in response to an obsession or according to rigid rules. Compulsions are aimed at reducing distress or preventing a feared outcome, but they are not connected to the feared outcome in a realistic way, or they are clearly excessive.
OCD affects an estimated 1 to 2 per cent of the population and typically begins in childhood, adolescence, or early adulthood. The condition causes significant functional impairment and is associated with reduced quality of life. Standard evidence-based treatment in the UK, as recommended by NICE, involves cognitive behavioural therapy with exposure and response prevention (CBT with ERP), and selective serotonin reuptake inhibitors (SSRIs) — typically at higher doses and for longer durations than used for depression. A proportion of patients do not respond adequately to these treatments, and there is a recognised need for additional therapeutic options.
Cannabis research on Obsessive-compulsive disorder
It is a 2011 commentary by Christopher Pittenger (Biological Psychiatry) on the methodological challenges of building valid animal models of OCD. The paper discusses the face validity, predictive validity, and construct validity of OCD animal models, reviews the neuroanatomical circuits implicated in OCD (caudate, anterior thalamus, orbitofrontal cortex, anterior cingulate), and notes that SSRIs are neither specific to OCD nor universally effective. The paper does not mention cannabis, cannabinoids, or the endocannabinoid system.
The published medical literature contains a small number of studies, none of which establishes treatment efficacy.
What clinical evidence exists
A 2026 review of new treatments for OCD, covering both cannabinoids and psychedelics, described the current evidence for cannabinoid use in OCD as “very small” and consisting of “survey-based, self-report studies with very few controlled trials” (PMID 41317726). This is not a description of a developing evidence base; it is a description of an evidence gap.
A 2025 systematic review and meta-analysis of cannabinoid formulations for anxiety-related disorders, Tourette syndrome, and OCD identified 21 randomised controlled trials in total. Of these, only 1 trial involved OCD (PMID 40956670). A single trial across the entire published literature, with no replication, does not establish treatment efficacy.
A 2019 review by Kayser and colleagues examined the endocannabinoid system as a potential treatment target for OCD and noted that “a growing body of basic and clinical research has showed that the endocannabinoid system plays a role” in OCD, but the clinical research referenced consisted largely of case reports, small uncontrolled series, and survey data (PMID 32656342). The review provides a mechanistic rationale, not clinical evidence.
Survey and self-report data
A 2021 internet survey by Kayser and colleagues examined patterns of cannabis use among individuals with OCD and found that most participants reported that cannabis improved their OCD symptoms (human observational, self-report survey, PMID 34336561). Internet surveys of self-selected respondents cannot establish efficacy. People who use cannabis and perceive benefit are more likely to respond to a survey about cannabis and OCD. The responses describe subjective experience, not treatment effect.
Case reports
A 2020 case report and literature review by Kayser and colleagues described symptomatic improvement with cannabis in a single patient with OCD and noted alignment with “data from a limited number of case studies and small controlled trials” (PMID 32848902). A case report is the lowest tier of clinical evidence. It describes what happened to one person and does not generalise.
Preclinical rationale
Preclinical research, including a 2026 study of CB2 receptor modulators on repetitive behaviours in animal models, provides a mechanistic basis for cannabinoid involvement in OCD-related circuits (PMID 41683609). This is laboratory research conducted in animals. The gap between preclinical mechanism and human treatment effect is large, and for OCD it has not been bridged.
A 2026 clinical trial of a medicinal cannabis plant extract (NTI164) in paediatric acute-onset neuropsychiatric syndrome (PANS), a condition that involves abrupt-onset OCD symptoms, found that the extract modified epigenetic, ribosomal, and immune pathways (PMID 41513541). This is not an OCD trial — PANS is a distinct clinical entity with a different aetiology — and the trial measured biological pathway changes, not OCD symptom outcomes.
Compounds studied for Obsessive-compulsive disorder
The endocannabinoid system is present in the brain circuits implicated in OCD, including the orbitofrontal cortex, anterior cingulate, caudate, and thalamus. This provides a plausible mechanistic rationale for cannabinoid involvement in OCD neurobiology. A plausible rationale is not clinical evidence.
CBD has the most preclinical support for effects on compulsive behaviour, largely from animal models. There is no human clinical trial of CBD as a treatment for OCD. A single RCT of a cannabinoid formulation in OCD exists in the published literature, but its identity and findings are not specified in the available systematic review; it has not been replicated.
THC has been described in case reports as producing symptomatic improvement in individual patients with OCD. Case reports do not establish efficacy and cannot separate pharmacological effect from expectation, placebo response, or the natural fluctuation of symptoms. THC can also increase anxiety, which is a core component of OCD, and the risk-benefit balance is unknown.
Linalool has anxiolytic properties demonstrated in animal models and human laboratory studies. Anxiety is a core driver of OCD symptoms, and preclinical anxiolytic effects provide a plausible mechanistic rationale for investigation, but no human OCD study of linalool exists.
Limonene has shown anxiolytic and antidepressant-like effects in preclinical research. No human OCD study of limonene exists.
Limits of the evidence for Obsessive-compulsive disorder
The evidence for cannabinoids as a treatment for OCD is very thin, and this should be stated plainly. Only one randomised controlled trial of a cannabinoid preparation for OCD exists in the published literature according to a 2025 systematic review, and it has not been replicated. The remaining evidence consists of internet surveys, case reports, and preclinical animal research. None of these study types can establish that a cannabinoid is a safe and effective treatment for OCD.
The survey data that report high rates of perceived benefit are subject to selection bias, recall bias, and placebo effect. People who use cannabis for OCD and find it unhelpful are less likely to participate in cannabis-and-OCD surveys. People who participate may attribute symptom fluctuation to cannabis when the improvement would have occurred anyway.
The preclinical rationale — endocannabinoid system involvement in OCD-related brain circuits — is scientifically valid but does not translate directly to a treatment recommendation. Many compounds with sound mechanistic rationales fail to demonstrate efficacy when tested in controlled human trials.
OCD is a condition for which effective evidence-based treatments exist (CBT with ERP, high-dose SSRIs, clomipramine). These are not perfect — a substantial minority of patients do not respond adequately — but they are backed by a large clinical trial literature. No cannabinoid-based approach has anything approaching this level of evidence.
Related conditions
- Anxiety disorders ; CBD laboratory studies and THC dose effects
- Autism ; trials of CBD-rich extracts
- Tourette’s syndrome ; two randomised trials, including CANNA-TICS
- Depression ; limited, mixed evidence
Read next
- CBD ; examined for effects on compulsive behaviour in preclinical models
- THC ; limited data on OCD symptoms
- Browse the cannabinoid reference
- Browse the terpene reference
Sources
1. Kayser RR, Snorrason I, Haney M, Simpson HB. The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? Cannabis and Cannabinoid Research. 2019;4(2):77-87. PMID: 32656342. Study record
2. Kayser RR, Saker S, Simpson HB. Cannabis Improves Obsessive-Compulsive Disorder — Case Report and Review of the Literature. Frontiers in Psychiatry. 2020;11:18. PMID: 32848902. Study record
3. Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Patterns of Cannabis Use Among Individuals with Obsessive-Compulsive Disorder: Results from an Internet Survey. Journal of Obsessive-Compulsive and Related Disorders. 2021;30:100658. PMID: 34336561. Study record
4. New treatments for OCD? Evidence for cannabinoids and psychedelics. 2026. PMID: 41317726. Study record
5. Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. 2025. PMID: 40956670. Study record
6. The Effect of SERM/CB2 Receptor Modulators on Repetitive Behaviours in an Animal Model. 2026. PMID: 41683609. Study record
7. Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome. 2026. PMID: 41513541. Study record
